*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Abbott Laboratories, with its substantial market cap of approximately $234 billion, is poised for its upcoming earnings release on July 17, 2025, amid investor anticipation of continued robust performance. The company's EPS estimate stands at $1.25, with a revenue forecast of $11.07 billion, reflecting its steady growth trajectory. Notably, the whisper number suggests a slightly higher EPS of $1.30, indicating market optimism for Abbott's ability to exceed expectations. This sentiment is likely fueled by Abbott's strategic focus on innovation within its medical devices and diagnostics segments, which have been key drivers of its financial success. As the healthcare landscape continues to evolve, Abbott's commitment to advancing its product offerings positions it well to capture further market share and deliver value to shareholders. Investors will be keenly watching to see if Abbott can leverage its strategic initiatives to surpass these expectations and sustain its growth momentum.
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Website: https://www.abbott.com
Average Sentiment Score:
Overall Sentiment: